$TELA 8-K SEC Filings

On October 8, 2026, TELA Bio, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). As of September 8, 2026, the record date for the Special Meeting, there were 45,143,410 outstanding shares of the Company’...

On October 5, 2026, TELA Bio, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Mark...

MALVERN, PA, October 5, 2026 -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the U.S. Food and Drug...

On September 28, 2026, TELA Bio, Inc. (the “Company”) entered into a Limited Consent to Credit Agreement and Guaranty (the “Limited Consent”) with Perceptive Credit Holdings V, LP, as administrative agent and collateral agent (the “Admin...

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.